Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the utilization of oncolytic viruses through an allogeneic cell-based delivery system. Calidi Biotherapeutics is advancing this potent stem cell and oncolytic virus (SN-V1c-vaccinia virus) combination for use in multiple difficult-to-treat oncology indications. Our team is also developing a universal cell delivery system to protect, amplify and potentiate oncolytic viruses currently in development.
In addition to the direct lytic effect that oncolytic viruses have on tumor cells, they also attract a variety of antigen-presenting and effector immune cells into the tumor. This leads to a significant upregulation of antigen presentation and enhancing the expression of numerous co-stimulatory, checkpoint, adhesion, and other molecules. This dynamic process combined with the virus-induced immunogenic cell death of tumor cells leads to the induction of potent systemic anti-tumor immunity. This approach has the potential to enhance the treatment effects of other immuno-oncology treatments including checkpoint inhibitors, co-stimulators, bi-specific T-cell engagers (BITEs) and chimeric antigen receptor (CAR) T-cell therapy. The ability to turn immunologically “cold tumors” into “hot ones” to improve patient outcomes has become a focus of numerous combinatorial treatment approaches with both approved therapies and new therapies currently under investigation.